Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2000 Sep;84(9):1064–1067. doi: 10.1136/bjo.84.9.1064

Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy

J Jonas 1, J Hayler 1, S Panda-Jonas 1
PMCID: PMC1723632  PMID: 10966969

Abstract

AIM—To report on clinical outcome and complications of intravitreal injection of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative vitreoretinopathy.
METHODS—The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy, who received an intravitreal injection of 10-20 mg crystalline triamcinolone acetonide at the end of surgery, and who were operated on by the same surgeon. Most of the vehicle of the solution containing the cortisone crystals was removed before performing the injection. Mean follow up time was 1.64 (SD 2.15) months (median 1.23 months; range 0.20-9.20 months). The study group was compared with a control group which consisted of 144 patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy performed by the same surgeon.
RESULTS—In the study group compared with the control group, intraocular inflammation, as estimated clinically by slit lamp biomicroscopy, was lower, appearance of the fundus upon ophthalmoscopy in the first postoperative week was clearer, and postoperative pain in the first two postoperative days was reduced. Intraocular pressure measured at the end of the first postoperative week did not vary significantly between the groups. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient. Postoperative infectious endophthalmitis was not encountered.
CONCLUSIONS—This pilot study suggests that intravitreal injection of crystalline cortisone with most of the vehicle removed is not toxic to intraocular structures, reduces postoperative intraocular inflammation, and may be a potentially useful additional tool in the treatment of proliferative vitreoretinopathy.



Full Text

The Full Text of this article is available as a PDF (96.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoszyk A. N., Gottlieb J. L., Machemer R., Hatchell D. L. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993;231(1):34–40. doi: 10.1007/BF01681698. [DOI] [PubMed] [Google Scholar]
  2. Binder S. Klinische und experimentelle Ergebnisse in der Behandlung der massiven periretinalen Proliferation (MPP), der prognostisch ungünstigsten Form der Netzhautablösung. Wien Klin Wochenschr Suppl. 1982;139:1–32. [PubMed] [Google Scholar]
  3. Blumenkranz M. S., Ophir A., Claflin A. J., Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982 Oct;94(4):458–467. doi: 10.1016/0002-9394(82)90239-2. [DOI] [PubMed] [Google Scholar]
  4. CORNMAN I. Selective damage to fibroblasts by desoxycorticosterone in cultures of mixed tissues. Science. 1951 Jan 12;113(2924):37–39. doi: 10.1126/science.113.2924.37. [DOI] [PubMed] [Google Scholar]
  5. Chandler D. B., Hida T., Sheta S., Proia A. D., Machemer R. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 1987;225(4):259–265. doi: 10.1007/BF02150144. [DOI] [PubMed] [Google Scholar]
  6. Coats M. L., Peyman G. A. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina. 1992;12(1):46–51. doi: 10.1097/00006982-199212010-00010. [DOI] [PubMed] [Google Scholar]
  7. Gasset A. R., Lorenzetti D. W., Ellison E. M., Kaufman H. E. Quantitative corticosteroid effect on corneal wound healing. Arch Ophthalmol. 1969 Apr;81(4):589–591. doi: 10.1001/archopht.1969.00990010591023. [DOI] [PubMed] [Google Scholar]
  8. Giles C. L. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol. 1974 Apr;77(4):438–441. doi: 10.1016/0002-9394(74)90449-8. [DOI] [PubMed] [Google Scholar]
  9. Gopal L., Bhende M., Sharma T. Vitrectomy for accidental intraocular steroid injection. Retina. 1995;15(4):295–299. doi: 10.1097/00006982-199515040-00005. [DOI] [PubMed] [Google Scholar]
  10. Graham R. O., Peyman G. A. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974 Aug;92(2):149–154. doi: 10.1001/archopht.1974.01010010155016. [DOI] [PubMed] [Google Scholar]
  11. Heffernan J. T., Futterman S., Kalina R. E. Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Invest Ophthalmol Vis Sci. 1978 Jun;17(6):565–568. [PubMed] [Google Scholar]
  12. Hida T., Chandler D., Arena J. E., Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986 Feb 15;101(2):190–195. doi: 10.1016/0002-9394(86)90593-3. [DOI] [PubMed] [Google Scholar]
  13. Jonas J. B., Hemmerling T. M., Budde W. M., Dinkel M. Postoperative analgesia by reinjections of local anesthetic through an indwelling retrobulbar catheter. Am J Ophthalmol. 2000 Jan;129(1):54–58. doi: 10.1016/s0002-9394(99)00256-1. [DOI] [PubMed] [Google Scholar]
  14. Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. Retina. 1996;16(2):166–167. [PubMed] [Google Scholar]
  15. Machemer R. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture. Invest Ophthalmol Vis Sci. 1988 Dec;29(12):1771–1783. [PubMed] [Google Scholar]
  16. Machemer R., Sugita G., Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171–180. [PMC free article] [PubMed] [Google Scholar]
  17. McCuen B. W., 2nd, Bessler M., Tano Y., Chandler D., Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981 Jun;91(6):785–788. doi: 10.1016/0002-9394(81)90013-1. [DOI] [PubMed] [Google Scholar]
  18. McLean E. B. Inadvertent injection of corticosteroid into the choroidal vasculature. Am J Ophthalmol. 1975 Nov;80(5):835–837. doi: 10.1016/0002-9394(75)90280-9. [DOI] [PubMed] [Google Scholar]
  19. Pratt W. B., Aronow L. The effect of glucocorticoids on protein and nucleic acid synthesis in mouse fibroblasts growing in vitro. J Biol Chem. 1966 Nov 25;241(22):5244–5250. [PubMed] [Google Scholar]
  20. Ruhmann A. G., Berliner D. L. Influence of steroids on fibroblasts. II. The fibroblast as an assay system for topical anti-inflammatory potency of corticosteroids. J Invest Dermatol. 1967 Aug;49(2):123–130. doi: 10.1038/jid.1967.113. [DOI] [PubMed] [Google Scholar]
  21. Schindler R. H., Chandler D., Thresher R., Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982 Apr;93(4):415–417. doi: 10.1016/0002-9394(82)90130-1. [DOI] [PubMed] [Google Scholar]
  22. Tano Y., Chandler D. B., McCuen B. W., Machemer R. Glucocorticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol. 1981 Feb;91(2):184–189. doi: 10.1016/0002-9394(81)90171-9. [DOI] [PubMed] [Google Scholar]
  23. Tano Y., Chandler D., Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980 Dec;90(6):810–816. doi: 10.1016/s0002-9394(14)75196-7. [DOI] [PubMed] [Google Scholar]
  24. Tano Y., Sugita G., Abrams G., Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980 Jan;89(1):131–136. doi: 10.1016/0002-9394(80)90239-1. [DOI] [PubMed] [Google Scholar]
  25. WOODS A. C. Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol. 1950 Sep;33(9):1325–1349. doi: 10.1016/0002-9394(50)91827-7. [DOI] [PubMed] [Google Scholar]
  26. Wiedemann P., Kirmani M., Santana M., Sorgente N., Ryan S. J. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch Clin Exp Ophthalmol. 1983;220(5):233–235. doi: 10.1007/BF02308080. [DOI] [PubMed] [Google Scholar]
  27. Zinn K. M. Iatrogenic intraocular injection of depot corticosteroid and its surgical removal using the pars plana approach. Ophthalmology. 1981 Jan;88(1):13–17. doi: 10.1016/s0161-6420(81)35081-7. [DOI] [PubMed] [Google Scholar]
  28. Zwaan J. The long-term effects of an accidental injection of depot corticosteroids in an infant eye. Ophthalmic Surg Lasers. 1997 Dec;28(12):1017–1019. [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES